Differential risk of adverse drug reactions with baricitinib across age groups: integrating real-world pharmacovigilance and genetic causal inference
This study highlights distinct age-dependent vulnerabilities to baricitinib-associated ADRs, with genetic evidence suggesting target-specific mechanisms underlying cardiovascular risk. These findings underscore the importance of age-tailored monitoring strategies and proactive pharmacovigilance in clinical practice.
Authors
- Mateng Chen
- Aidong Li (ORCID: https://orcid.org/0000-0003-3628-0393)
- Hanjiang Liu
- Ye Zhang (ORCID: https://orcid.org/0009-0008-7238-1013)
- Huiqiong Zeng (ORCID: https://orcid.org/0000-0002-2124-1837)
- Xiaojuan Li (ORCID: https://orcid.org/0000-0002-5187-1821)
- Wei Liu (ORCID: https://orcid.org/0009-0006-8142-0489)
- Gaofeng Xiong
- Junda Lai
Institutions
- Guangdong Pharmaceutical University (CN)
- Shenzhen Maternity and Child Healthcare Hospital (CN)
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (CN)
- Southern Medical University Shenzhen Hospital (CN)
- Community Health Center (US)
- Shenzhen Second People's Hospital (CN)
- Beijing Sport University (CN)
Publication Details
- Journal
- Therapeutic Advances in Drug Safety
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1177/20420986251406106
- Citations
- 1
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 1.31